Results from two separate phase III trials that have enrolled SMA type 1 patients with one or two copies of SMN2 (NCT03837184) and that have pre-symptomatic patients with two or three copies of SMN2 (NCT03505099) are currently awaited. Here, SMN2 is linked to spinal muscular atrophy, type 1.